Search results
Safe and Effective? The New York Times Revisits the COVID Jab. - The American Spectator | USA News...
American Spectator· 21 hours agoIt has taken three years, but the New York Times has finally admitted that maybe, just maybe, there are some serious side effects to COVID vaccines. < ...
Covaxin has excellent safety record, says Bharat Biotech
Investing.com· 3 days agoCovaxin has excellent safety record, says Bharat Biotech
AP source: J&J doses to be released, but many will be tossed
AOL· 4 days agoU.S. regulators are allowing for the release of 10 million doses of Johnson & Johnson's COVID-19 ...
Fmr. Biden Admin officials testify on pressuring Big Tech to censor pandemic posts
WJLA· 3 days agoOn Wednesday, former Biden Administration officials were summoned to Capitol Hill to testify in a...
Pandemic treaty will give WHO power to demand 20pc of British vaccines
Daily Telegraph· 6 days agoBritain was among the first countries to develop and roll out a Covid vaccine, the AstraZeneca jab,...
A Better Concept For mRNA Vaccines: Self-Amplification
Forbes· 6 days agoTwo new self-amplifying mRNA vaccines herald a new era of vaccination for coronaviruses.
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 3 days agoPfizer- $10.58 bn In the midst of the waning demand for Pfizer’sCovid-19 vaccine and antiviral Paxlovid (nirmatrelvir + ritonavir), ...
Plea in SC seeks medical panel under retired apex court judge to examine Covishield side effects
Investing.com· 4 days agoPlea in SC seeks medical panel under retired apex court judge to examine Covishield side effects
We May Be Facing an Epidemic of This Brain Disease
Mercola· 6 days agoIn my 2021 interview with Stephanie Seneff, Ph.D., she explained why she suspected the COVID shots may eventually result in an avalanche of neurological prion-based diseases ...
Earnings call: Daiichi Sankyo posts strong FY 2023 results, plans growth
Investing.com· 6 days agoThe pharmaceutical company's strong performance was primarily driven by robust sales of its key...